TT-00420

Phase 3Small molecule

TTransThera Sciences (Nanjing), Inc.

TT-00420 is one of 91 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholangiocarcinomaActive, not recruiting

Breast CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

Intrahepatic CholangiocarcinomaPhase 3

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

CholangiocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

TT-00420

TTransThera Sciences (Nanjing), Inc.

Phase 3

1 2

Zinecard

CChildren's Oncology Group

Preclinical

2 3

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

Calendula

OOHSU Knight Cancer Institute

Preclinical

1 6

Cyclophosphamide or Azathioprine

SSun Yat-sen University

Preclinical

1 7

Maxigesic

YYonsei University

Preclinical

1 8

Carbon Dye

FFujian Medical University Union Hospital

Preclinical

2 9

Epirubicin-Cyclophosphamide

GGBG Forschungs GmbH

Preclinical

1 10

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Phase II Clinical Study

NCT07052253

Q4 2030

Phase 3Not yet recruiting

Intrahepatic Cholangiocarcinoma

NCT07328919

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed·TTransThera Sciences (Nanjing), Inc.·Phase 1/2·NCT04742959·203 enrolled

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Completed·TTransThera Sciences (Nanjing), Inc.·Phase 1/2·NCT05253053·84 enrolled

Cholangiocarcinoma2 trials

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed·TTransThera Sciences (Nanjing), Inc.·Phase 2·NCT04919642·55 enrolled

Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Active, not recruiting·TTransThera Sciences (Nanjing), Inc.·Phase 2·NCT06057571·50 enrolled

Breast Cancer1 trial

Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

Completed·TTransThera Sciences (Nanjing), Inc.·Phase 1·NCT03654547·48 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

Not yet recruiting·TTransThera Sciences (Nanjing), Inc.·Phase 3·NCT07328919·138 enrolled

Phase II Clinical Study1 trial

A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Recruiting·AAkeso·Phase 2·NCT07052253·100 enrolled

1 more indication

Unspecified1 trial

Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers

Completed·TTransThera Sciences (Nanjing), Inc.·Phase 1·NCT04705922·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for TT-00420. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TT-00420 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TT-00420. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TransThera Sciences (Nanjing), Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTransThera Sciences (Nanjing), Inc.

TT-00420

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2030

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

Cholangiocarcinoma2 trials

Breast Cancer1 trial

Intrahepatic Cholangiocarcinoma1 trial

Phase II Clinical Study1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News